Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Worth Up to $464m Advances MEI Drug, Diversifies Helsinn's Portfolio

Executive Summary

Helsinn will help MEI Pharma advance its HDAC inhibitor pracinostat into Phase III development via a partnership worth up to $464m.

Advertisement

Related Content

Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal
Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer
Case Studies: How Three Public Companies Financed R&D In A Tough Market
MEI Pharma plummets on Phase II HDAC data
Helsinn’s Family-Business Approach Goes Global In Cancer Care

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel